STOCK TITAN

Allogene (NASDAQ: ALLO) insider files to sell 35,700 shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Allogene Therapeutics insider Zachary Roberts has filed a Form 144 notice to sell 35,700 shares of common stock, with an aggregate market value of $63,353.22, through Morgan Stanley Smith Barney on NASDAQ around February 2, 2026.

The shares were acquired on January 31, 2026 via restricted stock vesting under a registered compensation plan, with 224,730,144 common shares outstanding. In the prior three months, Roberts sold 26,269 common shares for gross proceeds of $40,979.64. The filer represents they are not aware of undisclosed material adverse information about Allogene.

Positive

  • None.

Negative

  • None.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Allogene (ALLO) Form 144 filed by Zachary Roberts disclose?

The Form 144 shows Zachary Roberts plans to sell 35,700 Allogene common shares on NASDAQ, valued at about $63,353.22. The shares came from restricted stock vesting under a registered compensation plan on January 31, 2026.

How many Allogene (ALLO) shares are outstanding in this Form 144?

The filing states there are 224,730,144 Allogene common shares outstanding. This figure provides context for the planned sale of 35,700 shares under Rule 144 and helps investors see how small the transaction is relative to total shares.

What prior Allogene (ALLO) stock sales by Zachary Roberts are reported?

Over the past three months, Zachary Roberts sold 26,269 Allogene common shares for gross proceeds of $40,979.64. This historical sale information is required in the Form 144 to show recent selling activity by the same person.

How were the Allogene (ALLO) shares in this Form 144 acquired?

The 35,700 shares were acquired as restricted stock vesting on January 31, 2026 under a registered equity compensation plan. The filing lists the issuer as the source and identifies the consideration as compensation, not a cash purchase.

Which broker and exchange are used for this Allogene (ALLO) Form 144 sale?

The planned sale will be executed through Morgan Stanley Smith Barney LLC Executive Financial Services on the NASDAQ exchange. The Form 144 lists the broker’s New York address and an approximate sale date of February 2, 2026.

What representation does the seller make in the Allogene (ALLO) Form 144?

By signing the notice, the seller represents they do not know any material adverse information about Allogene’s current or prospective operations that has not been publicly disclosed, as required for sales relying on Rule 144.
Allogene Therapeutics

NASDAQ:ALLO

ALLO Rankings

ALLO Latest News

ALLO Latest SEC Filings

ALLO Stock Data

420.25M
158.71M
17.45%
74.09%
8.99%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SOUTH SAN FRANCISCO